Skip to main content

White paper

Clinicogenomics: Linked data advances research

Clinicogenomics data can fuel all stages of development.



Since the human genome was first sequenced, life sciences researchers have sought to use this information to improve health. But they soon discovered that DNA sequence data alone has limited value when trying to understand the effects of genetic variation on health.

Today, researchers are increasingly linking genomic data to rich, longitudinal clinical information — a practice that yields clinicogenomics data. The field of clinicogenomics is unlocking novel insights to better understand diseases and to guide drug discovery, development and commercialization.

The study of clinicogenomics across large, diverse populations can help researchers:

  • Better understand disease pathways
  • Discover novel therapeutic targets
  • Identify variation in disease onset and progression
  • Evaluate drug safety and efficacy

Our latest white paper details the foundations of genomics-driven research and the sources of clinicogenomics data. It also highlights the ways clinicogenomics data can enhance clinical trials and fuel discovery and development of safer, more effective drugs.

Visit the Optum Life Sciences home page to see how we connect the health system and help life sciences organizations put evidence into action.

Related content

Accelerate drug development with clinicogenomic RWE

Optum, Novartis and GuardantINFORM experts discuss the ever-increasing importance of clinicogenomic data during this Endpoints News webinar.

Clinicogenomics: The next big leap in real-world data

Optum clinical genomics is positioned to shape a new generation of evidence that accelerates understanding of disease.

Realizing the full potential of clinicogenomics

Join Optum genomics experts as they discuss the progress being made to develop datasets that will aid in drug discovery and development.

Interested in learning more?

Connect with our clinicogenomics experts today.